Is XGN or ACH more profitable?

Accendra Health has a net margin of -11.41% compared to Exagen's net margin of -26.61%. Accendra Health's return on equity of -4.02% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% Accendra Health -11.41% -4.02% 0.70%

Does the media prefer XGN or ACH?

In the previous week, Exagen had 5 more articles in the media than Accendra Health. MarketBeat recorded 6 mentions for Exagen and 1 mentions for Accendra Health. Accendra Health's average media sentiment score of 0.90 beat Exagen's score of 0.77 indicating that Accendra Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Accendra Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ACH or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to Accendra Health's net margin of -11.41%. Accendra Health's return on equity of -4.02% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets Accendra Health -11.41% -4.02% 0.70% LifeMD 0.10% -168.23% -31.27%

Does the media refer more to ACH or LFMD?

In the previous week, LifeMD had 1 more articles in the media than Accendra Health. MarketBeat recorded 2 mentions for LifeMD and 1 mentions for Accendra Health. Accendra Health's average media sentiment score of 0.90 beat LifeMD's score of 0.89 indicating that Accendra Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accendra Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LifeMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate JYNT or ACH?

Accendra Health has a consensus price target of $1.50, suggesting a potential upside of 110.14%. Given Accendra Health's stronger consensus rating and higher possible upside, analysts clearly believe Accendra Health is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Accendra Health 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is JYNT or ACH more profitable?

Joint has a net margin of 6.49% compared to Accendra Health's net margin of -11.41%. Joint's return on equity of 12.02% beat Accendra Health's return on equity. Company Net Margins Return on Equity Return on Assets Joint 6.49% 12.02% 3.47% Accendra Health -11.41% -4.02% 0.70%

Does the media favor JYNT or ACH?

In the previous week, Joint had 3 more articles in the media than Accendra Health. MarketBeat recorded 4 mentions for Joint and 1 mentions for Accendra Health. Accendra Health's average media sentiment score of 0.90 beat Joint's score of 0.60 indicating that Accendra Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Joint 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Accendra Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACH or PARK?

In the previous week, Park Dental Partners had 3 more articles in the media than Accendra Health. MarketBeat recorded 4 mentions for Park Dental Partners and 1 mentions for Accendra Health. Accendra Health's average media sentiment score of 0.90 beat Park Dental Partners' score of 0.70 indicating that Accendra Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accendra Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Park Dental Partners 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PIII or ACH?

In the previous week, P3 Health Partners had 1 more articles in the media than Accendra Health. MarketBeat recorded 2 mentions for P3 Health Partners and 1 mentions for Accendra Health. P3 Health Partners' average media sentiment score of 0.91 beat Accendra Health's score of 0.90 indicating that P3 Health Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment P3 Health Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Accendra Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Accendra Health (ACH) Competitors

$0.71 -0.02 (-2.65%)

As of 09/25/2026 03:58 PM Eastern

Compare

ACH vs. XGN, LFMD, JYNT, PARK, and PIII

Should you buy Accendra Health stock or one of its competitors? Accendra Health's main competitors and comparable companies include Exagen (XGN), LifeMD (LFMD), Joint (JYNT), Park Dental Partners (PARK), and P3 Health Partners (PIII). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Accendra Health compare to Exagen?

Exagen (NASDAQ:XGN) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Exagen has higher earnings, but lower revenue than Accendra Health. Exagen is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$71.12M	2.97	-$19.95M	-$0.81	N/A
Accendra Health	$2.65B	0.02	-$1.10B	-$3.91	N/A

Accendra Health has a net margin of -11.41% compared to Exagen's net margin of -26.61%. Accendra Health's return on equity of -4.02% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Accendra Health	-11.41%	-4.02%	0.70%

In the previous week, Exagen had 5 more articles in the media than Accendra Health. MarketBeat recorded 6 mentions for Exagen and 1 mentions for Accendra Health. Accendra Health's average media sentiment score of 0.90 beat Exagen's score of 0.77 indicating that Accendra Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Accendra Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exagen presently has a consensus target price of $9.63, indicating a potential upside of 10.38%. Accendra Health has a consensus target price of $1.50, indicating a potential upside of 110.14%. Given Accendra Health's higher possible upside, analysts plainly believe Accendra Health is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Exagen has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

75.3% of Exagen shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Comparatively, 2.3% of Accendra Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Exagen beats Accendra Health on 10 of the 17 factors compared between the two stocks.

How does Accendra Health compare to LifeMD?

Accendra Health (NYSE:ACH) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Accendra Health presently has a consensus price target of $1.50, indicating a potential upside of 110.14%. LifeMD has a consensus price target of $7.57, indicating a potential upside of 154.93%. Given LifeMD's stronger consensus rating and higher possible upside, analysts plainly believe LifeMD is more favorable than Accendra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

LifeMD has a net margin of 0.10% compared to Accendra Health's net margin of -11.41%. Accendra Health's return on equity of -4.02% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accendra Health	-11.41%	-4.02%	0.70%
LifeMD	0.10%	-168.23%	-31.27%

In the previous week, LifeMD had 1 more articles in the media than Accendra Health. MarketBeat recorded 2 mentions for LifeMD and 1 mentions for Accendra Health. Accendra Health's average media sentiment score of 0.90 beat LifeMD's score of 0.89 indicating that Accendra Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accendra Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeMD has lower revenue, but higher earnings than Accendra Health. LifeMD is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accendra Health	$2.65B	0.02	-$1.10B	-$3.91	N/A
LifeMD	$191.59M	0.75	$14.35M	-$0.05	N/A

35.5% of LifeMD shares are held by institutional investors. 2.3% of Accendra Health shares are held by company insiders. Comparatively, 17.2% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Accendra Health has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, LifeMD has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Summary

LifeMD beats Accendra Health on 11 of the 16 factors compared between the two stocks.

How does Accendra Health compare to Joint?

Joint (NASDAQ:JYNT) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, Joint had 3 more articles in the media than Accendra Health. MarketBeat recorded 4 mentions for Joint and 1 mentions for Accendra Health. Accendra Health's average media sentiment score of 0.90 beat Joint's score of 0.60 indicating that Accendra Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Joint	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Accendra Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

76.9% of Joint shares are owned by institutional investors. 30.2% of Joint shares are owned by insiders. Comparatively, 2.3% of Accendra Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Joint has higher earnings, but lower revenue than Accendra Health. Accendra Health is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.12	$2.91M	$0.27	30.48
Accendra Health	$2.65B	0.02	-$1.10B	-$3.91	N/A

Joint has a net margin of 6.49% compared to Accendra Health's net margin of -11.41%. Joint's return on equity of 12.02% beat Accendra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
Accendra Health	-11.41%	-4.02%	0.70%

Joint has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Accendra Health has a consensus price target of $1.50, suggesting a potential upside of 110.14%. Given Accendra Health's stronger consensus rating and higher possible upside, analysts clearly believe Accendra Health is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Joint beats Accendra Health on 10 of the 15 factors compared between the two stocks.

How does Accendra Health compare to Park Dental Partners?

Accendra Health (NYSE:ACH) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

In the previous week, Park Dental Partners had 3 more articles in the media than Accendra Health. MarketBeat recorded 4 mentions for Park Dental Partners and 1 mentions for Accendra Health. Accendra Health's average media sentiment score of 0.90 beat Park Dental Partners' score of 0.70 indicating that Accendra Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accendra Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Park Dental Partners	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Accendra Health currently has a consensus target price of $1.50, suggesting a potential upside of 110.14%. Park Dental Partners has a consensus target price of $28.50, suggesting a potential upside of 43.14%. Given Accendra Health's higher probable upside, equities analysts plainly believe Accendra Health is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Park Dental Partners has a net margin of 0.00% compared to Accendra Health's net margin of -11.41%. Park Dental Partners' return on equity of 0.00% beat Accendra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accendra Health	-11.41%	-4.02%	0.70%
Park Dental Partners	N/A	N/A	N/A

Park Dental Partners has lower revenue, but higher earnings than Accendra Health. Accendra Health is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accendra Health	$2.65B	0.02	-$1.10B	-$3.91	N/A
Park Dental Partners	$244.49M	0.39	-$360K	$1.05	18.96

Summary

Park Dental Partners beats Accendra Health on 10 of the 14 factors compared between the two stocks.

How does Accendra Health compare to P3 Health Partners?

P3 Health Partners (NASDAQ:PIII) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

P3 Health Partners has higher earnings, but lower revenue than Accendra Health. P3 Health Partners is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.04	-$147.95M	-$33.00	N/A
Accendra Health	$2.65B	0.02	-$1.10B	-$3.91	N/A

In the previous week, P3 Health Partners had 1 more articles in the media than Accendra Health. MarketBeat recorded 2 mentions for P3 Health Partners and 1 mentions for Accendra Health. P3 Health Partners' average media sentiment score of 0.91 beat Accendra Health's score of 0.90 indicating that P3 Health Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
P3 Health Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Accendra Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

P3 Health Partners has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

P3 Health Partners presently has a consensus target price of $17.00, suggesting a potential upside of 141.13%. Accendra Health has a consensus target price of $1.50, suggesting a potential upside of 110.14%. Given P3 Health Partners' stronger consensus rating and higher possible upside, equities analysts clearly believe P3 Health Partners is more favorable than Accendra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

7.8% of P3 Health Partners shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by company insiders. Comparatively, 2.3% of Accendra Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

P3 Health Partners has a net margin of -6.55% compared to Accendra Health's net margin of -11.41%. P3 Health Partners' return on equity of 0.00% beat Accendra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
Accendra Health	-11.41%	-4.02%	0.70%

Summary

P3 Health Partners beats Accendra Health on 12 of the 16 factors compared between the two stocks.

Get Accendra Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACH vs. The Competition

Export

Metric	Accendra Health	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$54.45M	$9.82B	$7.33B	$22.98B
Dividend Yield	N/A	2.59%	2.52%	3.68%
P/E Ratio	-0.18	35.06	275.82	28.00
Price / Sales	0.02	5.59	635.50	88.74
Price / Cash	0.19	123.01	79.52	41.27
Price / Book	-0.12	5.24	10.44	4.66
Net Income	-$1.10B	$315.70M	$3.51B	$1.07B
7 Day Performance	-23.30%	0.71%	-1.31%	-1.12%
1 Month Performance	-41.25%	0.14%	-4.61%	-5.10%
1 Year Performance	N/A	16.65%	15.01%	7.73%

Accendra Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACH Accendra Health	1.7198 of 5 stars	$0.71 -2.6%	$1.50 +110.1%	N/A	$54.45M	$2.65B	N/A	6,500	News Coverage
XGN Exagen	3.0613 of 5 stars	$8.79 +2.8%	$9.63 +9.5%	-19.9%	$213.08M	$71.12M	N/A	220
LFMD LifeMD	3.2212 of 5 stars	$2.93 -4.1%	$7.57 +158.9%	-53.8%	$140.99M	$191.59M	N/A	384
JYNT Joint	1.8946 of 5 stars	$8.34 0.0%	N/A	-16.6%	$118.07M	$54.90M	30.93	330	News Coverage Positive News
PARK Park Dental Partners	4.1179 of 5 stars	$19.84 -1.7%	$28.50 +43.6%	N/A	$94.45M	$244.49M	18.90	1,212	Positive News Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ACH) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Accendra Health (ACH) Competitors

ACH vs. XGN, LFMD, JYNT, PARK, and PIII

How does Accendra Health compare to Exagen?

Summary

How does Accendra Health compare to LifeMD?

Summary

How does Accendra Health compare to Joint?

Summary

How does Accendra Health compare to Park Dental Partners?

Summary

How does Accendra Health compare to P3 Health Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACH vs. The Competition

Accendra Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Accendra Health (ACH) Competitors

ACH vs. XGN, LFMD, JYNT, PARK, and PIII

How does Accendra Health compare to Exagen?

Which has higher earnings and valuation, XGN or ACH?

Is XGN or ACH more profitable?

Does the media prefer XGN or ACH?

Do analysts prefer XGN or ACH?

Which has more volatility and risk, XGN or ACH?

Do insiders & institutionals have more ownership in XGN or ACH?

Summary

How does Accendra Health compare to LifeMD?

Do analysts prefer ACH or LFMD?

Is ACH or LFMD more profitable?

Does the media refer more to ACH or LFMD?

Which has better earnings and valuation, ACH or LFMD?

Do insiders and institutionals believe in ACH or LFMD?

Which has more risk & volatility, ACH or LFMD?

Summary

How does Accendra Health compare to Joint?

Does the media favor JYNT or ACH?

Do insiders and institutionals hold more shares of JYNT or ACH?

Which has better valuation & earnings, JYNT or ACH?

Is JYNT or ACH more profitable?

Which has more risk and volatility, JYNT or ACH?

Do analysts rate JYNT or ACH?

Summary

How does Accendra Health compare to Park Dental Partners?

Does the media prefer ACH or PARK?

Do analysts recommend ACH or PARK?

Is ACH or PARK more profitable?

Which has higher valuation and earnings, ACH or PARK?

Summary

How does Accendra Health compare to P3 Health Partners?

Which has stronger valuation and earnings, PIII or ACH?

Does the media prefer PIII or ACH?

Which has more risk & volatility, PIII or ACH?

Do analysts rate PIII or ACH?

Do institutionals & insiders have more ownership in PIII or ACH?

Is PIII or ACH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACH vs. The Competition

Accendra Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools